Global Short-acting Recombinant Human Erythropoietin Drugs Supply, Demand and Key Producers, 2023-2029
The global Short-acting Recombinant Human Erythropoietin Drugs market size is expected to reach $ 14300 million by 2029, rising at a market growth of 6.1% CAGR during the forecast period (2023-2029).
The market for short-acting recombinant human erythropoietin drugs is currently in a steady growth phase, with its size gradually expanding, and sales continuing to rise. These drugs find extensive use in the treatment of anemia, especially in patients with chronic kidney disease, cancer chemotherapy recipients, and individuals requiring correction of hemoglobin levels pre-surgery. Future developments may include further expansion into additional clinical applications and more convenient administration routes, along with improved manufacturing techniques to meet the growing healthcare demands.
Erythropoietin is produced by interstitial fibroblasts in the kidney in close association with peritubular capillary and proximal convoluted tubule. It is also produced in perisinusoidal cells in the liver. While liver production predominates in the fetal and perinatal period, renal production is predominant during adulthood.
This report studies the global Short-acting Recombinant Human Erythropoietin Drugs production, demand, key manufacturers, and key regions.
This report is a detailed and comprehensive analysis of the world market for Short-acting Recombinant Human Erythropoietin Drugs, and provides market size (US$ million) and Year-over-Year (YoY) Growth, considering 2022 as the base year. This report explores demand trends and competition, as well as details the characteristics of Short-acting Recombinant Human Erythropoietin Drugs that contribute to its increasing demand across many markets.
Highlights and key features of the study
Global Short-acting Recombinant Human Erythropoietin Drugs total production and demand, 2018-2029, (K Units)
Global Short-acting Recombinant Human Erythropoietin Drugs total production value, 2018-2029, (USD Million)
Global Short-acting Recombinant Human Erythropoietin Drugs production by region & country, production, value, CAGR, 2018-2029, (USD Million) & (K Units)
Global Short-acting Recombinant Human Erythropoietin Drugs consumption by region & country, CAGR, 2018-2029 & (K Units)
U.S. VS China: Short-acting Recombinant Human Erythropoietin Drugs domestic production, consumption, key domestic manufacturers and share
Global Short-acting Recombinant Human Erythropoietin Drugs production by manufacturer, production, price, value and market share 2018-2023, (USD Million) & (K Units)
Global Short-acting Recombinant Human Erythropoietin Drugs production by Type, production, value, CAGR, 2018-2029, (USD Million) & (K Units)
Global Short-acting Recombinant Human Erythropoietin Drugs production by Application production, value, CAGR, 2018-2029, (USD Million) & (K Units).
This reports profiles key players in the global Short-acting Recombinant Human Erythropoietin Drugs market based on the following parameters – company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Amgen, Johnson & Johnson, Roche, Kyowa Kirin, LG Chem, Daewoong Pharmaceutical, Wockhardt, CJ Healthcare and 3SBio, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the World Short-acting Recombinant Human Erythropoietin Drugs market.
Detailed Segmentation:
Each section contains quantitative market data including market by value (US$ Millions), volume (production, consumption) & (K Units) and average price (US$/Unit) by manufacturer, by Type, and by Application. Data is given for the years 2018-2029 by year with 2022 as the base year, 2023 as the estimate year, and 2024-2029 as the forecast year.
Global Short-acting Recombinant Human Erythropoietin Drugs Market, By Region:
1. How big is the global Short-acting Recombinant Human Erythropoietin Drugs market?
2. What is the demand of the global Short-acting Recombinant Human Erythropoietin Drugs market?
3. What is the year over year growth of the global Short-acting Recombinant Human Erythropoietin Drugs market?
4. What is the production and production value of the global Short-acting Recombinant Human Erythropoietin Drugs market?
5. Who are the key producers in the global Short-acting Recombinant Human Erythropoietin Drugs market?
The market for short-acting recombinant human erythropoietin drugs is currently in a steady growth phase, with its size gradually expanding, and sales continuing to rise. These drugs find extensive use in the treatment of anemia, especially in patients with chronic kidney disease, cancer chemotherapy recipients, and individuals requiring correction of hemoglobin levels pre-surgery. Future developments may include further expansion into additional clinical applications and more convenient administration routes, along with improved manufacturing techniques to meet the growing healthcare demands.
Erythropoietin is produced by interstitial fibroblasts in the kidney in close association with peritubular capillary and proximal convoluted tubule. It is also produced in perisinusoidal cells in the liver. While liver production predominates in the fetal and perinatal period, renal production is predominant during adulthood.
This report studies the global Short-acting Recombinant Human Erythropoietin Drugs production, demand, key manufacturers, and key regions.
This report is a detailed and comprehensive analysis of the world market for Short-acting Recombinant Human Erythropoietin Drugs, and provides market size (US$ million) and Year-over-Year (YoY) Growth, considering 2022 as the base year. This report explores demand trends and competition, as well as details the characteristics of Short-acting Recombinant Human Erythropoietin Drugs that contribute to its increasing demand across many markets.
Highlights and key features of the study
Global Short-acting Recombinant Human Erythropoietin Drugs total production and demand, 2018-2029, (K Units)
Global Short-acting Recombinant Human Erythropoietin Drugs total production value, 2018-2029, (USD Million)
Global Short-acting Recombinant Human Erythropoietin Drugs production by region & country, production, value, CAGR, 2018-2029, (USD Million) & (K Units)
Global Short-acting Recombinant Human Erythropoietin Drugs consumption by region & country, CAGR, 2018-2029 & (K Units)
U.S. VS China: Short-acting Recombinant Human Erythropoietin Drugs domestic production, consumption, key domestic manufacturers and share
Global Short-acting Recombinant Human Erythropoietin Drugs production by manufacturer, production, price, value and market share 2018-2023, (USD Million) & (K Units)
Global Short-acting Recombinant Human Erythropoietin Drugs production by Type, production, value, CAGR, 2018-2029, (USD Million) & (K Units)
Global Short-acting Recombinant Human Erythropoietin Drugs production by Application production, value, CAGR, 2018-2029, (USD Million) & (K Units).
This reports profiles key players in the global Short-acting Recombinant Human Erythropoietin Drugs market based on the following parameters – company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Amgen, Johnson & Johnson, Roche, Kyowa Kirin, LG Chem, Daewoong Pharmaceutical, Wockhardt, CJ Healthcare and 3SBio, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the World Short-acting Recombinant Human Erythropoietin Drugs market.
Detailed Segmentation:
Each section contains quantitative market data including market by value (US$ Millions), volume (production, consumption) & (K Units) and average price (US$/Unit) by manufacturer, by Type, and by Application. Data is given for the years 2018-2029 by year with 2022 as the base year, 2023 as the estimate year, and 2024-2029 as the forecast year.
Global Short-acting Recombinant Human Erythropoietin Drugs Market, By Region:
- United States
- China
- Europe
- Japan
- South Korea
- ASEAN
- India
- Rest of World
- Epoetin-alfa
- Epoetin-beta
- Darbepoetin-alfa
- Others
- Anemia
- Kidney Disorders
- Others
- Amgen
- Johnson & Johnson
- Roche
- Kyowa Kirin
- LG Chem
- Daewoong Pharmaceutical
- Wockhardt
- CJ Healthcare
- 3SBio
- Kexing Biopharm
- Harbin Pharmaceutical Group
- Beijing Four Rings Bio-Pharmaceutical
1. How big is the global Short-acting Recombinant Human Erythropoietin Drugs market?
2. What is the demand of the global Short-acting Recombinant Human Erythropoietin Drugs market?
3. What is the year over year growth of the global Short-acting Recombinant Human Erythropoietin Drugs market?
4. What is the production and production value of the global Short-acting Recombinant Human Erythropoietin Drugs market?
5. Who are the key producers in the global Short-acting Recombinant Human Erythropoietin Drugs market?
1 SUPPLY SUMMARY
1.1 Short-acting Recombinant Human Erythropoietin Drugs Introduction
1.2 World Short-acting Recombinant Human Erythropoietin Drugs Supply & Forecast
1.2.1 World Short-acting Recombinant Human Erythropoietin Drugs Production Value (2018 & 2022 & 2029)
1.2.2 World Short-acting Recombinant Human Erythropoietin Drugs Production (2018-2029)
1.2.3 World Short-acting Recombinant Human Erythropoietin Drugs Pricing Trends (2018-2029)
1.3 World Short-acting Recombinant Human Erythropoietin Drugs Production by Region (Based on Production Site)
1.3.1 World Short-acting Recombinant Human Erythropoietin Drugs Production Value by Region (2018-2029)
1.3.2 World Short-acting Recombinant Human Erythropoietin Drugs Production by Region (2018-2029)
1.3.3 World Short-acting Recombinant Human Erythropoietin Drugs Average Price by Region (2018-2029)
1.3.4 North America Short-acting Recombinant Human Erythropoietin Drugs Production (2018-2029)
1.3.5 Europe Short-acting Recombinant Human Erythropoietin Drugs Production (2018-2029)
1.3.6 China Short-acting Recombinant Human Erythropoietin Drugs Production (2018-2029)
1.3.7 Japan Short-acting Recombinant Human Erythropoietin Drugs Production (2018-2029)
1.4 Market Drivers, Restraints and Trends
1.4.1 Short-acting Recombinant Human Erythropoietin Drugs Market Drivers
1.4.2 Factors Affecting Demand
1.4.3 Short-acting Recombinant Human Erythropoietin Drugs Major Market Trends
2 DEMAND SUMMARY
2.1 World Short-acting Recombinant Human Erythropoietin Drugs Demand (2018-2029)
2.2 World Short-acting Recombinant Human Erythropoietin Drugs Consumption by Region
2.2.1 World Short-acting Recombinant Human Erythropoietin Drugs Consumption by Region (2018-2023)
2.2.2 World Short-acting Recombinant Human Erythropoietin Drugs Consumption Forecast by Region (2024-2029)
2.3 United States Short-acting Recombinant Human Erythropoietin Drugs Consumption (2018-2029)
2.4 China Short-acting Recombinant Human Erythropoietin Drugs Consumption (2018-2029)
2.5 Europe Short-acting Recombinant Human Erythropoietin Drugs Consumption (2018-2029)
2.6 Japan Short-acting Recombinant Human Erythropoietin Drugs Consumption (2018-2029)
2.7 South Korea Short-acting Recombinant Human Erythropoietin Drugs Consumption (2018-2029)
2.8 ASEAN Short-acting Recombinant Human Erythropoietin Drugs Consumption (2018-2029)
2.9 India Short-acting Recombinant Human Erythropoietin Drugs Consumption (2018-2029)
3 WORLD SHORT-ACTING RECOMBINANT HUMAN ERYTHROPOIETIN DRUGS MANUFACTURERS COMPETITIVE ANALYSIS
3.1 World Short-acting Recombinant Human Erythropoietin Drugs Production Value by Manufacturer (2018-2023)
3.2 World Short-acting Recombinant Human Erythropoietin Drugs Production by Manufacturer (2018-2023)
3.3 World Short-acting Recombinant Human Erythropoietin Drugs Average Price by Manufacturer (2018-2023)
3.4 Short-acting Recombinant Human Erythropoietin Drugs Company Evaluation Quadrant
3.5 Industry Rank and Concentration Rate (CR)
3.5.1 Global Short-acting Recombinant Human Erythropoietin Drugs Industry Rank of Major Manufacturers
3.5.2 Global Concentration Ratios (CR4) for Short-acting Recombinant Human Erythropoietin Drugs in 2022
3.5.3 Global Concentration Ratios (CR8) for Short-acting Recombinant Human Erythropoietin Drugs in 2022
3.6 Short-acting Recombinant Human Erythropoietin Drugs Market: Overall Company Footprint Analysis
3.6.1 Short-acting Recombinant Human Erythropoietin Drugs Market: Region Footprint
3.6.2 Short-acting Recombinant Human Erythropoietin Drugs Market: Company Product Type Footprint
3.6.3 Short-acting Recombinant Human Erythropoietin Drugs Market: Company Product Application Footprint
3.7 Competitive Environment
3.7.1 Historical Structure of the Industry
3.7.2 Barriers of Market Entry
3.7.3 Factors of Competition
3.8 New Entrant and Capacity Expansion Plans
3.9 Mergers, Acquisition, Agreements, and Collaborations
4 UNITED STATES VS CHINA VS REST OF THE WORLD
4.1 United States VS China: Short-acting Recombinant Human Erythropoietin Drugs Production Value Comparison
4.1.1 United States VS China: Short-acting Recombinant Human Erythropoietin Drugs Production Value Comparison (2018 & 2022 & 2029)
4.1.2 United States VS China: Short-acting Recombinant Human Erythropoietin Drugs Production Value Market Share Comparison (2018 & 2022 & 2029)
4.2 United States VS China: Short-acting Recombinant Human Erythropoietin Drugs Production Comparison
4.2.1 United States VS China: Short-acting Recombinant Human Erythropoietin Drugs Production Comparison (2018 & 2022 & 2029)
4.2.2 United States VS China: Short-acting Recombinant Human Erythropoietin Drugs Production Market Share Comparison (2018 & 2022 & 2029)
4.3 United States VS China: Short-acting Recombinant Human Erythropoietin Drugs Consumption Comparison
4.3.1 United States VS China: Short-acting Recombinant Human Erythropoietin Drugs Consumption Comparison (2018 & 2022 & 2029)
4.3.2 United States VS China: Short-acting Recombinant Human Erythropoietin Drugs Consumption Market Share Comparison (2018 & 2022 & 2029)
4.4 United States Based Short-acting Recombinant Human Erythropoietin Drugs Manufacturers and Market Share, 2018-2023
4.4.1 United States Based Short-acting Recombinant Human Erythropoietin Drugs Manufacturers, Headquarters and Production Site (States, Country)
4.4.2 United States Based Manufacturers Short-acting Recombinant Human Erythropoietin Drugs Production Value (2018-2023)
4.4.3 United States Based Manufacturers Short-acting Recombinant Human Erythropoietin Drugs Production (2018-2023)
4.5 China Based Short-acting Recombinant Human Erythropoietin Drugs Manufacturers and Market Share
4.5.1 China Based Short-acting Recombinant Human Erythropoietin Drugs Manufacturers, Headquarters and Production Site (Province, Country)
4.5.2 China Based Manufacturers Short-acting Recombinant Human Erythropoietin Drugs Production Value (2018-2023)
4.5.3 China Based Manufacturers Short-acting Recombinant Human Erythropoietin Drugs Production (2018-2023)
4.6 Rest of World Based Short-acting Recombinant Human Erythropoietin Drugs Manufacturers and Market Share, 2018-2023
4.6.1 Rest of World Based Short-acting Recombinant Human Erythropoietin Drugs Manufacturers, Headquarters and Production Site (State, Country)
4.6.2 Rest of World Based Manufacturers Short-acting Recombinant Human Erythropoietin Drugs Production Value (2018-2023)
4.6.3 Rest of World Based Manufacturers Short-acting Recombinant Human Erythropoietin Drugs Production (2018-2023)
5 MARKET ANALYSIS BY TYPE
5.1 World Short-acting Recombinant Human Erythropoietin Drugs Market Size Overview by Type: 2018 VS 2022 VS 2029
5.2 Segment Introduction by Type
5.2.1 Epoetin-alfa
5.2.2 Epoetin-beta
5.2.3 Darbepoetin-alfa
5.2.4 Others
5.3 Market Segment by Type
5.3.1 World Short-acting Recombinant Human Erythropoietin Drugs Production by Type (2018-2029)
5.3.2 World Short-acting Recombinant Human Erythropoietin Drugs Production Value by Type (2018-2029)
5.3.3 World Short-acting Recombinant Human Erythropoietin Drugs Average Price by Type (2018-2029)
6 MARKET ANALYSIS BY APPLICATION
6.1 World Short-acting Recombinant Human Erythropoietin Drugs Market Size Overview by Application: 2018 VS 2022 VS 2029
6.2 Segment Introduction by Application
6.2.1 Anemia
6.2.2 Kidney Disorders
6.2.3 Others
6.3 Market Segment by Application
6.3.1 World Short-acting Recombinant Human Erythropoietin Drugs Production by Application (2018-2029)
6.3.2 World Short-acting Recombinant Human Erythropoietin Drugs Production Value by Application (2018-2029)
6.3.3 World Short-acting Recombinant Human Erythropoietin Drugs Average Price by Application (2018-2029)
7 COMPANY PROFILES
7.1 Amgen
7.1.1 Amgen Details
7.1.2 Amgen Major Business
7.1.3 Amgen Short-acting Recombinant Human Erythropoietin Drugs Product and Services
7.1.4 Amgen Short-acting Recombinant Human Erythropoietin Drugs Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.1.5 Amgen Recent Developments/Updates
7.1.6 Amgen Competitive Strengths & Weaknesses
7.2 Johnson & Johnson
7.2.1 Johnson & Johnson Details
7.2.2 Johnson & Johnson Major Business
7.2.3 Johnson & Johnson Short-acting Recombinant Human Erythropoietin Drugs Product and Services
7.2.4 Johnson & Johnson Short-acting Recombinant Human Erythropoietin Drugs Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.2.5 Johnson & Johnson Recent Developments/Updates
7.2.6 Johnson & Johnson Competitive Strengths & Weaknesses
7.3 Roche
7.3.1 Roche Details
7.3.2 Roche Major Business
7.3.3 Roche Short-acting Recombinant Human Erythropoietin Drugs Product and Services
7.3.4 Roche Short-acting Recombinant Human Erythropoietin Drugs Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.3.5 Roche Recent Developments/Updates
7.3.6 Roche Competitive Strengths & Weaknesses
7.4 Kyowa Kirin
7.4.1 Kyowa Kirin Details
7.4.2 Kyowa Kirin Major Business
7.4.3 Kyowa Kirin Short-acting Recombinant Human Erythropoietin Drugs Product and Services
7.4.4 Kyowa Kirin Short-acting Recombinant Human Erythropoietin Drugs Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.4.5 Kyowa Kirin Recent Developments/Updates
7.4.6 Kyowa Kirin Competitive Strengths & Weaknesses
7.5 LG Chem
7.5.1 LG Chem Details
7.5.2 LG Chem Major Business
7.5.3 LG Chem Short-acting Recombinant Human Erythropoietin Drugs Product and Services
7.5.4 LG Chem Short-acting Recombinant Human Erythropoietin Drugs Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.5.5 LG Chem Recent Developments/Updates
7.5.6 LG Chem Competitive Strengths & Weaknesses
7.6 Daewoong Pharmaceutical
7.6.1 Daewoong Pharmaceutical Details
7.6.2 Daewoong Pharmaceutical Major Business
7.6.3 Daewoong Pharmaceutical Short-acting Recombinant Human Erythropoietin Drugs Product and Services
7.6.4 Daewoong Pharmaceutical Short-acting Recombinant Human Erythropoietin Drugs Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.6.5 Daewoong Pharmaceutical Recent Developments/Updates
7.6.6 Daewoong Pharmaceutical Competitive Strengths & Weaknesses
7.7 Wockhardt
7.7.1 Wockhardt Details
7.7.2 Wockhardt Major Business
7.7.3 Wockhardt Short-acting Recombinant Human Erythropoietin Drugs Product and Services
7.7.4 Wockhardt Short-acting Recombinant Human Erythropoietin Drugs Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.7.5 Wockhardt Recent Developments/Updates
7.7.6 Wockhardt Competitive Strengths & Weaknesses
7.8 CJ Healthcare
7.8.1 CJ Healthcare Details
7.8.2 CJ Healthcare Major Business
7.8.3 CJ Healthcare Short-acting Recombinant Human Erythropoietin Drugs Product and Services
7.8.4 CJ Healthcare Short-acting Recombinant Human Erythropoietin Drugs Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.8.5 CJ Healthcare Recent Developments/Updates
7.8.6 CJ Healthcare Competitive Strengths & Weaknesses
7.9 3SBio
7.9.1 3SBio Details
7.9.2 3SBio Major Business
7.9.3 3SBio Short-acting Recombinant Human Erythropoietin Drugs Product and Services
7.9.4 3SBio Short-acting Recombinant Human Erythropoietin Drugs Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.9.5 3SBio Recent Developments/Updates
7.9.6 3SBio Competitive Strengths & Weaknesses
7.10 Kexing Biopharm
7.10.1 Kexing Biopharm Details
7.10.2 Kexing Biopharm Major Business
7.10.3 Kexing Biopharm Short-acting Recombinant Human Erythropoietin Drugs Product and Services
7.10.4 Kexing Biopharm Short-acting Recombinant Human Erythropoietin Drugs Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.10.5 Kexing Biopharm Recent Developments/Updates
7.10.6 Kexing Biopharm Competitive Strengths & Weaknesses
7.11 Harbin Pharmaceutical Group
7.11.1 Harbin Pharmaceutical Group Details
7.11.2 Harbin Pharmaceutical Group Major Business
7.11.3 Harbin Pharmaceutical Group Short-acting Recombinant Human Erythropoietin Drugs Product and Services
7.11.4 Harbin Pharmaceutical Group Short-acting Recombinant Human Erythropoietin Drugs Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.11.5 Harbin Pharmaceutical Group Recent Developments/Updates
7.11.6 Harbin Pharmaceutical Group Competitive Strengths & Weaknesses
7.12 Beijing Four Rings Bio-Pharmaceutical
7.12.1 Beijing Four Rings Bio-Pharmaceutical Details
7.12.2 Beijing Four Rings Bio-Pharmaceutical Major Business
7.12.3 Beijing Four Rings Bio-Pharmaceutical Short-acting Recombinant Human Erythropoietin Drugs Product and Services
7.12.4 Beijing Four Rings Bio-Pharmaceutical Short-acting Recombinant Human Erythropoietin Drugs Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.12.5 Beijing Four Rings Bio-Pharmaceutical Recent Developments/Updates
7.12.6 Beijing Four Rings Bio-Pharmaceutical Competitive Strengths & Weaknesses
8 INDUSTRY CHAIN ANALYSIS
8.1 Short-acting Recombinant Human Erythropoietin Drugs Industry Chain
8.2 Short-acting Recombinant Human Erythropoietin Drugs Upstream Analysis
8.2.1 Short-acting Recombinant Human Erythropoietin Drugs Core Raw Materials
8.2.2 Main Manufacturers of Short-acting Recombinant Human Erythropoietin Drugs Core Raw Materials
8.3 Midstream Analysis
8.4 Downstream Analysis
8.5 Short-acting Recombinant Human Erythropoietin Drugs Production Mode
8.6 Short-acting Recombinant Human Erythropoietin Drugs Procurement Model
8.7 Short-acting Recombinant Human Erythropoietin Drugs Industry Sales Model and Sales Channels
8.7.1 Short-acting Recombinant Human Erythropoietin Drugs Sales Model
8.7.2 Short-acting Recombinant Human Erythropoietin Drugs Typical Customers
9 RESEARCH FINDINGS AND CONCLUSION
10 APPENDIX
10.1 Methodology
10.2 Research Process and Data Source
10.3 Disclaimer
1.1 Short-acting Recombinant Human Erythropoietin Drugs Introduction
1.2 World Short-acting Recombinant Human Erythropoietin Drugs Supply & Forecast
1.2.1 World Short-acting Recombinant Human Erythropoietin Drugs Production Value (2018 & 2022 & 2029)
1.2.2 World Short-acting Recombinant Human Erythropoietin Drugs Production (2018-2029)
1.2.3 World Short-acting Recombinant Human Erythropoietin Drugs Pricing Trends (2018-2029)
1.3 World Short-acting Recombinant Human Erythropoietin Drugs Production by Region (Based on Production Site)
1.3.1 World Short-acting Recombinant Human Erythropoietin Drugs Production Value by Region (2018-2029)
1.3.2 World Short-acting Recombinant Human Erythropoietin Drugs Production by Region (2018-2029)
1.3.3 World Short-acting Recombinant Human Erythropoietin Drugs Average Price by Region (2018-2029)
1.3.4 North America Short-acting Recombinant Human Erythropoietin Drugs Production (2018-2029)
1.3.5 Europe Short-acting Recombinant Human Erythropoietin Drugs Production (2018-2029)
1.3.6 China Short-acting Recombinant Human Erythropoietin Drugs Production (2018-2029)
1.3.7 Japan Short-acting Recombinant Human Erythropoietin Drugs Production (2018-2029)
1.4 Market Drivers, Restraints and Trends
1.4.1 Short-acting Recombinant Human Erythropoietin Drugs Market Drivers
1.4.2 Factors Affecting Demand
1.4.3 Short-acting Recombinant Human Erythropoietin Drugs Major Market Trends
2 DEMAND SUMMARY
2.1 World Short-acting Recombinant Human Erythropoietin Drugs Demand (2018-2029)
2.2 World Short-acting Recombinant Human Erythropoietin Drugs Consumption by Region
2.2.1 World Short-acting Recombinant Human Erythropoietin Drugs Consumption by Region (2018-2023)
2.2.2 World Short-acting Recombinant Human Erythropoietin Drugs Consumption Forecast by Region (2024-2029)
2.3 United States Short-acting Recombinant Human Erythropoietin Drugs Consumption (2018-2029)
2.4 China Short-acting Recombinant Human Erythropoietin Drugs Consumption (2018-2029)
2.5 Europe Short-acting Recombinant Human Erythropoietin Drugs Consumption (2018-2029)
2.6 Japan Short-acting Recombinant Human Erythropoietin Drugs Consumption (2018-2029)
2.7 South Korea Short-acting Recombinant Human Erythropoietin Drugs Consumption (2018-2029)
2.8 ASEAN Short-acting Recombinant Human Erythropoietin Drugs Consumption (2018-2029)
2.9 India Short-acting Recombinant Human Erythropoietin Drugs Consumption (2018-2029)
3 WORLD SHORT-ACTING RECOMBINANT HUMAN ERYTHROPOIETIN DRUGS MANUFACTURERS COMPETITIVE ANALYSIS
3.1 World Short-acting Recombinant Human Erythropoietin Drugs Production Value by Manufacturer (2018-2023)
3.2 World Short-acting Recombinant Human Erythropoietin Drugs Production by Manufacturer (2018-2023)
3.3 World Short-acting Recombinant Human Erythropoietin Drugs Average Price by Manufacturer (2018-2023)
3.4 Short-acting Recombinant Human Erythropoietin Drugs Company Evaluation Quadrant
3.5 Industry Rank and Concentration Rate (CR)
3.5.1 Global Short-acting Recombinant Human Erythropoietin Drugs Industry Rank of Major Manufacturers
3.5.2 Global Concentration Ratios (CR4) for Short-acting Recombinant Human Erythropoietin Drugs in 2022
3.5.3 Global Concentration Ratios (CR8) for Short-acting Recombinant Human Erythropoietin Drugs in 2022
3.6 Short-acting Recombinant Human Erythropoietin Drugs Market: Overall Company Footprint Analysis
3.6.1 Short-acting Recombinant Human Erythropoietin Drugs Market: Region Footprint
3.6.2 Short-acting Recombinant Human Erythropoietin Drugs Market: Company Product Type Footprint
3.6.3 Short-acting Recombinant Human Erythropoietin Drugs Market: Company Product Application Footprint
3.7 Competitive Environment
3.7.1 Historical Structure of the Industry
3.7.2 Barriers of Market Entry
3.7.3 Factors of Competition
3.8 New Entrant and Capacity Expansion Plans
3.9 Mergers, Acquisition, Agreements, and Collaborations
4 UNITED STATES VS CHINA VS REST OF THE WORLD
4.1 United States VS China: Short-acting Recombinant Human Erythropoietin Drugs Production Value Comparison
4.1.1 United States VS China: Short-acting Recombinant Human Erythropoietin Drugs Production Value Comparison (2018 & 2022 & 2029)
4.1.2 United States VS China: Short-acting Recombinant Human Erythropoietin Drugs Production Value Market Share Comparison (2018 & 2022 & 2029)
4.2 United States VS China: Short-acting Recombinant Human Erythropoietin Drugs Production Comparison
4.2.1 United States VS China: Short-acting Recombinant Human Erythropoietin Drugs Production Comparison (2018 & 2022 & 2029)
4.2.2 United States VS China: Short-acting Recombinant Human Erythropoietin Drugs Production Market Share Comparison (2018 & 2022 & 2029)
4.3 United States VS China: Short-acting Recombinant Human Erythropoietin Drugs Consumption Comparison
4.3.1 United States VS China: Short-acting Recombinant Human Erythropoietin Drugs Consumption Comparison (2018 & 2022 & 2029)
4.3.2 United States VS China: Short-acting Recombinant Human Erythropoietin Drugs Consumption Market Share Comparison (2018 & 2022 & 2029)
4.4 United States Based Short-acting Recombinant Human Erythropoietin Drugs Manufacturers and Market Share, 2018-2023
4.4.1 United States Based Short-acting Recombinant Human Erythropoietin Drugs Manufacturers, Headquarters and Production Site (States, Country)
4.4.2 United States Based Manufacturers Short-acting Recombinant Human Erythropoietin Drugs Production Value (2018-2023)
4.4.3 United States Based Manufacturers Short-acting Recombinant Human Erythropoietin Drugs Production (2018-2023)
4.5 China Based Short-acting Recombinant Human Erythropoietin Drugs Manufacturers and Market Share
4.5.1 China Based Short-acting Recombinant Human Erythropoietin Drugs Manufacturers, Headquarters and Production Site (Province, Country)
4.5.2 China Based Manufacturers Short-acting Recombinant Human Erythropoietin Drugs Production Value (2018-2023)
4.5.3 China Based Manufacturers Short-acting Recombinant Human Erythropoietin Drugs Production (2018-2023)
4.6 Rest of World Based Short-acting Recombinant Human Erythropoietin Drugs Manufacturers and Market Share, 2018-2023
4.6.1 Rest of World Based Short-acting Recombinant Human Erythropoietin Drugs Manufacturers, Headquarters and Production Site (State, Country)
4.6.2 Rest of World Based Manufacturers Short-acting Recombinant Human Erythropoietin Drugs Production Value (2018-2023)
4.6.3 Rest of World Based Manufacturers Short-acting Recombinant Human Erythropoietin Drugs Production (2018-2023)
5 MARKET ANALYSIS BY TYPE
5.1 World Short-acting Recombinant Human Erythropoietin Drugs Market Size Overview by Type: 2018 VS 2022 VS 2029
5.2 Segment Introduction by Type
5.2.1 Epoetin-alfa
5.2.2 Epoetin-beta
5.2.3 Darbepoetin-alfa
5.2.4 Others
5.3 Market Segment by Type
5.3.1 World Short-acting Recombinant Human Erythropoietin Drugs Production by Type (2018-2029)
5.3.2 World Short-acting Recombinant Human Erythropoietin Drugs Production Value by Type (2018-2029)
5.3.3 World Short-acting Recombinant Human Erythropoietin Drugs Average Price by Type (2018-2029)
6 MARKET ANALYSIS BY APPLICATION
6.1 World Short-acting Recombinant Human Erythropoietin Drugs Market Size Overview by Application: 2018 VS 2022 VS 2029
6.2 Segment Introduction by Application
6.2.1 Anemia
6.2.2 Kidney Disorders
6.2.3 Others
6.3 Market Segment by Application
6.3.1 World Short-acting Recombinant Human Erythropoietin Drugs Production by Application (2018-2029)
6.3.2 World Short-acting Recombinant Human Erythropoietin Drugs Production Value by Application (2018-2029)
6.3.3 World Short-acting Recombinant Human Erythropoietin Drugs Average Price by Application (2018-2029)
7 COMPANY PROFILES
7.1 Amgen
7.1.1 Amgen Details
7.1.2 Amgen Major Business
7.1.3 Amgen Short-acting Recombinant Human Erythropoietin Drugs Product and Services
7.1.4 Amgen Short-acting Recombinant Human Erythropoietin Drugs Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.1.5 Amgen Recent Developments/Updates
7.1.6 Amgen Competitive Strengths & Weaknesses
7.2 Johnson & Johnson
7.2.1 Johnson & Johnson Details
7.2.2 Johnson & Johnson Major Business
7.2.3 Johnson & Johnson Short-acting Recombinant Human Erythropoietin Drugs Product and Services
7.2.4 Johnson & Johnson Short-acting Recombinant Human Erythropoietin Drugs Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.2.5 Johnson & Johnson Recent Developments/Updates
7.2.6 Johnson & Johnson Competitive Strengths & Weaknesses
7.3 Roche
7.3.1 Roche Details
7.3.2 Roche Major Business
7.3.3 Roche Short-acting Recombinant Human Erythropoietin Drugs Product and Services
7.3.4 Roche Short-acting Recombinant Human Erythropoietin Drugs Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.3.5 Roche Recent Developments/Updates
7.3.6 Roche Competitive Strengths & Weaknesses
7.4 Kyowa Kirin
7.4.1 Kyowa Kirin Details
7.4.2 Kyowa Kirin Major Business
7.4.3 Kyowa Kirin Short-acting Recombinant Human Erythropoietin Drugs Product and Services
7.4.4 Kyowa Kirin Short-acting Recombinant Human Erythropoietin Drugs Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.4.5 Kyowa Kirin Recent Developments/Updates
7.4.6 Kyowa Kirin Competitive Strengths & Weaknesses
7.5 LG Chem
7.5.1 LG Chem Details
7.5.2 LG Chem Major Business
7.5.3 LG Chem Short-acting Recombinant Human Erythropoietin Drugs Product and Services
7.5.4 LG Chem Short-acting Recombinant Human Erythropoietin Drugs Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.5.5 LG Chem Recent Developments/Updates
7.5.6 LG Chem Competitive Strengths & Weaknesses
7.6 Daewoong Pharmaceutical
7.6.1 Daewoong Pharmaceutical Details
7.6.2 Daewoong Pharmaceutical Major Business
7.6.3 Daewoong Pharmaceutical Short-acting Recombinant Human Erythropoietin Drugs Product and Services
7.6.4 Daewoong Pharmaceutical Short-acting Recombinant Human Erythropoietin Drugs Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.6.5 Daewoong Pharmaceutical Recent Developments/Updates
7.6.6 Daewoong Pharmaceutical Competitive Strengths & Weaknesses
7.7 Wockhardt
7.7.1 Wockhardt Details
7.7.2 Wockhardt Major Business
7.7.3 Wockhardt Short-acting Recombinant Human Erythropoietin Drugs Product and Services
7.7.4 Wockhardt Short-acting Recombinant Human Erythropoietin Drugs Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.7.5 Wockhardt Recent Developments/Updates
7.7.6 Wockhardt Competitive Strengths & Weaknesses
7.8 CJ Healthcare
7.8.1 CJ Healthcare Details
7.8.2 CJ Healthcare Major Business
7.8.3 CJ Healthcare Short-acting Recombinant Human Erythropoietin Drugs Product and Services
7.8.4 CJ Healthcare Short-acting Recombinant Human Erythropoietin Drugs Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.8.5 CJ Healthcare Recent Developments/Updates
7.8.6 CJ Healthcare Competitive Strengths & Weaknesses
7.9 3SBio
7.9.1 3SBio Details
7.9.2 3SBio Major Business
7.9.3 3SBio Short-acting Recombinant Human Erythropoietin Drugs Product and Services
7.9.4 3SBio Short-acting Recombinant Human Erythropoietin Drugs Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.9.5 3SBio Recent Developments/Updates
7.9.6 3SBio Competitive Strengths & Weaknesses
7.10 Kexing Biopharm
7.10.1 Kexing Biopharm Details
7.10.2 Kexing Biopharm Major Business
7.10.3 Kexing Biopharm Short-acting Recombinant Human Erythropoietin Drugs Product and Services
7.10.4 Kexing Biopharm Short-acting Recombinant Human Erythropoietin Drugs Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.10.5 Kexing Biopharm Recent Developments/Updates
7.10.6 Kexing Biopharm Competitive Strengths & Weaknesses
7.11 Harbin Pharmaceutical Group
7.11.1 Harbin Pharmaceutical Group Details
7.11.2 Harbin Pharmaceutical Group Major Business
7.11.3 Harbin Pharmaceutical Group Short-acting Recombinant Human Erythropoietin Drugs Product and Services
7.11.4 Harbin Pharmaceutical Group Short-acting Recombinant Human Erythropoietin Drugs Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.11.5 Harbin Pharmaceutical Group Recent Developments/Updates
7.11.6 Harbin Pharmaceutical Group Competitive Strengths & Weaknesses
7.12 Beijing Four Rings Bio-Pharmaceutical
7.12.1 Beijing Four Rings Bio-Pharmaceutical Details
7.12.2 Beijing Four Rings Bio-Pharmaceutical Major Business
7.12.3 Beijing Four Rings Bio-Pharmaceutical Short-acting Recombinant Human Erythropoietin Drugs Product and Services
7.12.4 Beijing Four Rings Bio-Pharmaceutical Short-acting Recombinant Human Erythropoietin Drugs Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.12.5 Beijing Four Rings Bio-Pharmaceutical Recent Developments/Updates
7.12.6 Beijing Four Rings Bio-Pharmaceutical Competitive Strengths & Weaknesses
8 INDUSTRY CHAIN ANALYSIS
8.1 Short-acting Recombinant Human Erythropoietin Drugs Industry Chain
8.2 Short-acting Recombinant Human Erythropoietin Drugs Upstream Analysis
8.2.1 Short-acting Recombinant Human Erythropoietin Drugs Core Raw Materials
8.2.2 Main Manufacturers of Short-acting Recombinant Human Erythropoietin Drugs Core Raw Materials
8.3 Midstream Analysis
8.4 Downstream Analysis
8.5 Short-acting Recombinant Human Erythropoietin Drugs Production Mode
8.6 Short-acting Recombinant Human Erythropoietin Drugs Procurement Model
8.7 Short-acting Recombinant Human Erythropoietin Drugs Industry Sales Model and Sales Channels
8.7.1 Short-acting Recombinant Human Erythropoietin Drugs Sales Model
8.7.2 Short-acting Recombinant Human Erythropoietin Drugs Typical Customers
9 RESEARCH FINDINGS AND CONCLUSION
10 APPENDIX
10.1 Methodology
10.2 Research Process and Data Source
10.3 Disclaimer
LIST OF TABLES
Table 1. World Short-acting Recombinant Human Erythropoietin Drugs Production Value by Region (2018, 2022 and 2029) & (USD Million)
Table 2. World Short-acting Recombinant Human Erythropoietin Drugs Production Value by Region (2018-2023) & (USD Million)
Table 3. World Short-acting Recombinant Human Erythropoietin Drugs Production Value by Region (2024-2029) & (USD Million)
Table 4. World Short-acting Recombinant Human Erythropoietin Drugs Production Value Market Share by Region (2018-2023)
Table 5. World Short-acting Recombinant Human Erythropoietin Drugs Production Value Market Share by Region (2024-2029)
Table 6. World Short-acting Recombinant Human Erythropoietin Drugs Production by Region (2018-2023) & (K Units)
Table 7. World Short-acting Recombinant Human Erythropoietin Drugs Production by Region (2024-2029) & (K Units)
Table 8. World Short-acting Recombinant Human Erythropoietin Drugs Production Market Share by Region (2018-2023)
Table 9. World Short-acting Recombinant Human Erythropoietin Drugs Production Market Share by Region (2024-2029)
Table 10. World Short-acting Recombinant Human Erythropoietin Drugs Average Price by Region (2018-2023) & (US$/Unit)
Table 11. World Short-acting Recombinant Human Erythropoietin Drugs Average Price by Region (2024-2029) & (US$/Unit)
Table 12. Short-acting Recombinant Human Erythropoietin Drugs Major Market Trends
Table 13. World Short-acting Recombinant Human Erythropoietin Drugs Consumption Growth Rate Forecast by Region (2018 & 2022 & 2029) & (K Units)
Table 14. World Short-acting Recombinant Human Erythropoietin Drugs Consumption by Region (2018-2023) & (K Units)
Table 15. World Short-acting Recombinant Human Erythropoietin Drugs Consumption Forecast by Region (2024-2029) & (K Units)
Table 16. World Short-acting Recombinant Human Erythropoietin Drugs Production Value by Manufacturer (2018-2023) & (USD Million)
Table 17. Production Value Market Share of Key Short-acting Recombinant Human Erythropoietin Drugs Producers in 2022
Table 18. World Short-acting Recombinant Human Erythropoietin Drugs Production by Manufacturer (2018-2023) & (K Units)
Table 19. Production Market Share of Key Short-acting Recombinant Human Erythropoietin Drugs Producers in 2022
Table 20. World Short-acting Recombinant Human Erythropoietin Drugs Average Price by Manufacturer (2018-2023) & (US$/Unit)
Table 21. Global Short-acting Recombinant Human Erythropoietin Drugs Company Evaluation Quadrant
Table 22. World Short-acting Recombinant Human Erythropoietin Drugs Industry Rank of Major Manufacturers, Based on Production Value in 2022
Table 23. Head Office and Short-acting Recombinant Human Erythropoietin Drugs Production Site of Key Manufacturer
Table 24. Short-acting Recombinant Human Erythropoietin Drugs Market: Company Product Type Footprint
Table 25. Short-acting Recombinant Human Erythropoietin Drugs Market: Company Product Application Footprint
Table 26. Short-acting Recombinant Human Erythropoietin Drugs Competitive Factors
Table 27. Short-acting Recombinant Human Erythropoietin Drugs New Entrant and Capacity Expansion Plans
Table 28. Short-acting Recombinant Human Erythropoietin Drugs Mergers & Acquisitions Activity
Table 29. United States VS China Short-acting Recombinant Human Erythropoietin Drugs Production Value Comparison, (2018 & 2022 & 2029) & (USD Million)
Table 30. United States VS China Short-acting Recombinant Human Erythropoietin Drugs Production Comparison, (2018 & 2022 & 2029) & (K Units)
Table 31. United States VS China Short-acting Recombinant Human Erythropoietin Drugs Consumption Comparison, (2018 & 2022 & 2029) & (K Units)
Table 32. United States Based Short-acting Recombinant Human Erythropoietin Drugs Manufacturers, Headquarters and Production Site (States, Country)
Table 33. United States Based Manufacturers Short-acting Recombinant Human Erythropoietin Drugs Production Value, (2018-2023) & (USD Million)
Table 34. United States Based Manufacturers Short-acting Recombinant Human Erythropoietin Drugs Production Value Market Share (2018-2023)
Table 35. United States Based Manufacturers Short-acting Recombinant Human Erythropoietin Drugs Production (2018-2023) & (K Units)
Table 36. United States Based Manufacturers Short-acting Recombinant Human Erythropoietin Drugs Production Market Share (2018-2023)
Table 37. China Based Short-acting Recombinant Human Erythropoietin Drugs Manufacturers, Headquarters and Production Site (Province, Country)
Table 38. China Based Manufacturers Short-acting Recombinant Human Erythropoietin Drugs Production Value, (2018-2023) & (USD Million)
Table 39. China Based Manufacturers Short-acting Recombinant Human Erythropoietin Drugs Production Value Market Share (2018-2023)
Table 40. China Based Manufacturers Short-acting Recombinant Human Erythropoietin Drugs Production (2018-2023) & (K Units)
Table 41. China Based Manufacturers Short-acting Recombinant Human Erythropoietin Drugs Production Market Share (2018-2023)
Table 42. Rest of World Based Short-acting Recombinant Human Erythropoietin Drugs Manufacturers, Headquarters and Production Site (States, Country)
Table 43. Rest of World Based Manufacturers Short-acting Recombinant Human Erythropoietin Drugs Production Value, (2018-2023) & (USD Million)
Table 44. Rest of World Based Manufacturers Short-acting Recombinant Human Erythropoietin Drugs Production Value Market Share (2018-2023)
Table 45. Rest of World Based Manufacturers Short-acting Recombinant Human Erythropoietin Drugs Production (2018-2023) & (K Units)
Table 46. Rest of World Based Manufacturers Short-acting Recombinant Human Erythropoietin Drugs Production Market Share (2018-2023)
Table 47. World Short-acting Recombinant Human Erythropoietin Drugs Production Value by Type, (USD Million), 2018 & 2022 & 2029
Table 48. World Short-acting Recombinant Human Erythropoietin Drugs Production by Type (2018-2023) & (K Units)
Table 49. World Short-acting Recombinant Human Erythropoietin Drugs Production by Type (2024-2029) & (K Units)
Table 50. World Short-acting Recombinant Human Erythropoietin Drugs Production Value by Type (2018-2023) & (USD Million)
Table 51. World Short-acting Recombinant Human Erythropoietin Drugs Production Value by Type (2024-2029) & (USD Million)
Table 52. World Short-acting Recombinant Human Erythropoietin Drugs Average Price by Type (2018-2023) & (US$/Unit)
Table 53. World Short-acting Recombinant Human Erythropoietin Drugs Average Price by Type (2024-2029) & (US$/Unit)
Table 54. World Short-acting Recombinant Human Erythropoietin Drugs Production Value by Application, (USD Million), 2018 & 2022 & 2029
Table 55. World Short-acting Recombinant Human Erythropoietin Drugs Production by Application (2018-2023) & (K Units)
Table 56. World Short-acting Recombinant Human Erythropoietin Drugs Production by Application (2024-2029) & (K Units)
Table 57. World Short-acting Recombinant Human Erythropoietin Drugs Production Value by Application (2018-2023) & (USD Million)
Table 58. World Short-acting Recombinant Human Erythropoietin Drugs Production Value by Application (2024-2029) & (USD Million)
Table 59. World Short-acting Recombinant Human Erythropoietin Drugs Average Price by Application (2018-2023) & (US$/Unit)
Table 60. World Short-acting Recombinant Human Erythropoietin Drugs Average Price by Application (2024-2029) & (US$/Unit)
Table 61. Amgen Basic Information, Manufacturing Base and Competitors
Table 62. Amgen Major Business
Table 63. Amgen Short-acting Recombinant Human Erythropoietin Drugs Product and Services
Table 64. Amgen Short-acting Recombinant Human Erythropoietin Drugs Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 65. Amgen Recent Developments/Updates
Table 66. Amgen Competitive Strengths & Weaknesses
Table 67. Johnson & Johnson Basic Information, Manufacturing Base and Competitors
Table 68. Johnson & Johnson Major Business
Table 69. Johnson & Johnson Short-acting Recombinant Human Erythropoietin Drugs Product and Services
Table 70. Johnson & Johnson Short-acting Recombinant Human Erythropoietin Drugs Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 71. Johnson & Johnson Recent Developments/Updates
Table 72. Johnson & Johnson Competitive Strengths & Weaknesses
Table 73. Roche Basic Information, Manufacturing Base and Competitors
Table 74. Roche Major Business
Table 75. Roche Short-acting Recombinant Human Erythropoietin Drugs Product and Services
Table 76. Roche Short-acting Recombinant Human Erythropoietin Drugs Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 77. Roche Recent Developments/Updates
Table 78. Roche Competitive Strengths & Weaknesses
Table 79. Kyowa Kirin Basic Information, Manufacturing Base and Competitors
Table 80. Kyowa Kirin Major Business
Table 81. Kyowa Kirin Short-acting Recombinant Human Erythropoietin Drugs Product and Services
Table 82. Kyowa Kirin Short-acting Recombinant Human Erythropoietin Drugs Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 83. Kyowa Kirin Recent Developments/Updates
Table 84. Kyowa Kirin Competitive Strengths & Weaknesses
Table 85. LG Chem Basic Information, Manufacturing Base and Competitors
Table 86. LG Chem Major Business
Table 87. LG Chem Short-acting Recombinant Human Erythropoietin Drugs Product and Services
Table 88. LG Chem Short-acting Recombinant Human Erythropoietin Drugs Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 89. LG Chem Recent Developments/Updates
Table 90. LG Chem Competitive Strengths & Weaknesses
Table 91. Daewoong Pharmaceutical Basic Information, Manufacturing Base and Competitors
Table 92. Daewoong Pharmaceutical Major Business
Table 93. Daewoong Pharmaceutical Short-acting Recombinant Human Erythropoietin Drugs Product and Services
Table 94. Daewoong Pharmaceutical Short-acting Recombinant Human Erythropoietin Drugs Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 95. Daewoong Pharmaceutical Recent Developments/Updates
Table 96. Daewoong Pharmaceutical Competitive Strengths & Weaknesses
Table 97. Wockhardt Basic Information, Manufacturing Base and Competitors
Table 98. Wockhardt Major Business
Table 99. Wockhardt Short-acting Recombinant Human Erythropoietin Drugs Product and Services
Table 100. Wockhardt Short-acting Recombinant Human Erythropoietin Drugs Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 101. Wockhardt Recent Developments/Updates
Table 102. Wockhardt Competitive Strengths & Weaknesses
Table 103. CJ Healthcare Basic Information, Manufacturing Base and Competitors
Table 104. CJ Healthcare Major Business
Table 105. CJ Healthcare Short-acting Recombinant Human Erythropoietin Drugs Product and Services
Table 106. CJ Healthcare Short-acting Recombinant Human Erythropoietin Drugs Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 107. CJ Healthcare Recent Developments/Updates
Table 108. CJ Healthcare Competitive Strengths & Weaknesses
Table 109. 3SBio Basic Information, Manufacturing Base and Competitors
Table 110. 3SBio Major Business
Table 111. 3SBio Short-acting Recombinant Human Erythropoietin Drugs Product and Services
Table 112. 3SBio Short-acting Recombinant Human Erythropoietin Drugs Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 113. 3SBio Recent Developments/Updates
Table 114. 3SBio Competitive Strengths & Weaknesses
Table 115. Kexing Biopharm Basic Information, Manufacturing Base and Competitors
Table 116. Kexing Biopharm Major Business
Table 117. Kexing Biopharm Short-acting Recombinant Human Erythropoietin Drugs Product and Services
Table 118. Kexing Biopharm Short-acting Recombinant Human Erythropoietin Drugs Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 119. Kexing Biopharm Recent Developments/Updates
Table 120. Kexing Biopharm Competitive Strengths & Weaknesses
Table 121. Harbin Pharmaceutical Group Basic Information, Manufacturing Base and Competitors
Table 122. Harbin Pharmaceutical Group Major Business
Table 123. Harbin Pharmaceutical Group Short-acting Recombinant Human Erythropoietin Drugs Product and Services
Table 124. Harbin Pharmaceutical Group Short-acting Recombinant Human Erythropoietin Drugs Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 125. Harbin Pharmaceutical Group Recent Developments/Updates
Table 126. Beijing Four Rings Bio-Pharmaceutical Basic Information, Manufacturing Base and Competitors
Table 127. Beijing Four Rings Bio-Pharmaceutical Major Business
Table 128. Beijing Four Rings Bio-Pharmaceutical Short-acting Recombinant Human Erythropoietin Drugs Product and Services
Table 129. Beijing Four Rings Bio-Pharmaceutical Short-acting Recombinant Human Erythropoietin Drugs Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 130. Global Key Players of Short-acting Recombinant Human Erythropoietin Drugs Upstream (Raw Materials)
Table 131. Short-acting Recombinant Human Erythropoietin Drugs Typical Customers
Table 132. Short-acting Recombinant Human Erythropoietin Drugs Typical Distributors
LIST OF FIGURE
Figure 1. Short-acting Recombinant Human Erythropoietin Drugs Picture
Figure 2. World Short-acting Recombinant Human Erythropoietin Drugs Production Value: 2018 & 2022 & 2029, (USD Million)
Figure 3. World Short-acting Recombinant Human Erythropoietin Drugs Production Value and Forecast (2018-2029) & (USD Million)
Figure 4. World Short-acting Recombinant Human Erythropoietin Drugs Production (2018-2029) & (K Units)
Figure 5. World Short-acting Recombinant Human Erythropoietin Drugs Average Price (2018-2029) & (US$/Unit)
Figure 6. World Short-acting Recombinant Human Erythropoietin Drugs Production Value Market Share by Region (2018-2029)
Figure 7. World Short-acting Recombinant Human Erythropoietin Drugs Production Market Share by Region (2018-2029)
Figure 8. North America Short-acting Recombinant Human Erythropoietin Drugs Production (2018-2029) & (K Units)
Figure 9. Europe Short-acting Recombinant Human Erythropoietin Drugs Production (2018-2029) & (K Units)
Figure 10. China Short-acting Recombinant Human Erythropoietin Drugs Production (2018-2029) & (K Units)
Figure 11. Japan Short-acting Recombinant Human Erythropoietin Drugs Production (2018-2029) & (K Units)
Figure 12. Short-acting Recombinant Human Erythropoietin Drugs Market Drivers
Figure 13. Factors Affecting Demand
Figure 14. World Short-acting Recombinant Human Erythropoietin Drugs Consumption (2018-2029) & (K Units)
Figure 15. World Short-acting Recombinant Human Erythropoietin Drugs Consumption Market Share by Region (2018-2029)
Figure 16. United States Short-acting Recombinant Human Erythropoietin Drugs Consumption (2018-2029) & (K Units)
Figure 17. China Short-acting Recombinant Human Erythropoietin Drugs Consumption (2018-2029) & (K Units)
Figure 18. Europe Short-acting Recombinant Human Erythropoietin Drugs Consumption (2018-2029) & (K Units)
Figure 19. Japan Short-acting Recombinant Human Erythropoietin Drugs Consumption (2018-2029) & (K Units)
Figure 20. South Korea Short-acting Recombinant Human Erythropoietin Drugs Consumption (2018-2029) & (K Units)
Figure 21. ASEAN Short-acting Recombinant Human Erythropoietin Drugs Consumption (2018-2029) & (K Units)
Figure 22. India Short-acting Recombinant Human Erythropoietin Drugs Consumption (2018-2029) & (K Units)
Figure 23. Producer Shipments of Short-acting Recombinant Human Erythropoietin Drugs by Manufacturer Revenue ($MM) and Market Share (%): 2022
Figure 24. Global Four-firm Concentration Ratios (CR4) for Short-acting Recombinant Human Erythropoietin Drugs Markets in 2022
Figure 25. Global Four-firm Concentration Ratios (CR8) for Short-acting Recombinant Human Erythropoietin Drugs Markets in 2022
Figure 26. United States VS China: Short-acting Recombinant Human Erythropoietin Drugs Production Value Market Share Comparison (2018 & 2022 & 2029)
Figure 27. United States VS China: Short-acting Recombinant Human Erythropoietin Drugs Production Market Share Comparison (2018 & 2022 & 2029)
Figure 28. United States VS China: Short-acting Recombinant Human Erythropoietin Drugs Consumption Market Share Comparison (2018 & 2022 & 2029)
Figure 29. United States Based Manufacturers Short-acting Recombinant Human Erythropoietin Drugs Production Market Share 2022
Figure 30. China Based Manufacturers Short-acting Recombinant Human Erythropoietin Drugs Production Market Share 2022
Figure 31. Rest of World Based Manufacturers Short-acting Recombinant Human Erythropoietin Drugs Production Market Share 2022
Figure 32. World Short-acting Recombinant Human Erythropoietin Drugs Production Value by Type, (USD Million), 2018 & 2022 & 2029
Figure 33. World Short-acting Recombinant Human Erythropoietin Drugs Production Value Market Share by Type in 2022
Figure 34. Epoetin-alfa
Figure 35. Epoetin-beta
Figure 36. Darbepoetin-alfa
Figure 37. Others
Figure 38. World Short-acting Recombinant Human Erythropoietin Drugs Production Market Share by Type (2018-2029)
Figure 39. World Short-acting Recombinant Human Erythropoietin Drugs Production Value Market Share by Type (2018-2029)
Figure 40. World Short-acting Recombinant Human Erythropoietin Drugs Average Price by Type (2018-2029) & (US$/Unit)
Figure 41. World Short-acting Recombinant Human Erythropoietin Drugs Production Value by Application, (USD Million), 2018 & 2022 & 2029
Figure 42. World Short-acting Recombinant Human Erythropoietin Drugs Production Value Market Share by Application in 2022
Figure 43. Anemia
Figure 44. Kidney Disorders
Figure 45. Others
Figure 46. World Short-acting Recombinant Human Erythropoietin Drugs Production Market Share by Application (2018-2029)
Figure 47. World Short-acting Recombinant Human Erythropoietin Drugs Production Value Market Share by Application (2018-2029)
Figure 48. World Short-acting Recombinant Human Erythropoietin Drugs Average Price by Application (2018-2029) & (US$/Unit)
Figure 49. Short-acting Recombinant Human Erythropoietin Drugs Industry Chain
Figure 50. Short-acting Recombinant Human Erythropoietin Drugs Procurement Model
Figure 51. Short-acting Recombinant Human Erythropoietin Drugs Sales Model
Figure 52. Short-acting Recombinant Human Erythropoietin Drugs Sales Channels, Direct Sales, and Distribution
Figure 53. Methodology
Figure 54. Research Process and Data Source
Table 1. World Short-acting Recombinant Human Erythropoietin Drugs Production Value by Region (2018, 2022 and 2029) & (USD Million)
Table 2. World Short-acting Recombinant Human Erythropoietin Drugs Production Value by Region (2018-2023) & (USD Million)
Table 3. World Short-acting Recombinant Human Erythropoietin Drugs Production Value by Region (2024-2029) & (USD Million)
Table 4. World Short-acting Recombinant Human Erythropoietin Drugs Production Value Market Share by Region (2018-2023)
Table 5. World Short-acting Recombinant Human Erythropoietin Drugs Production Value Market Share by Region (2024-2029)
Table 6. World Short-acting Recombinant Human Erythropoietin Drugs Production by Region (2018-2023) & (K Units)
Table 7. World Short-acting Recombinant Human Erythropoietin Drugs Production by Region (2024-2029) & (K Units)
Table 8. World Short-acting Recombinant Human Erythropoietin Drugs Production Market Share by Region (2018-2023)
Table 9. World Short-acting Recombinant Human Erythropoietin Drugs Production Market Share by Region (2024-2029)
Table 10. World Short-acting Recombinant Human Erythropoietin Drugs Average Price by Region (2018-2023) & (US$/Unit)
Table 11. World Short-acting Recombinant Human Erythropoietin Drugs Average Price by Region (2024-2029) & (US$/Unit)
Table 12. Short-acting Recombinant Human Erythropoietin Drugs Major Market Trends
Table 13. World Short-acting Recombinant Human Erythropoietin Drugs Consumption Growth Rate Forecast by Region (2018 & 2022 & 2029) & (K Units)
Table 14. World Short-acting Recombinant Human Erythropoietin Drugs Consumption by Region (2018-2023) & (K Units)
Table 15. World Short-acting Recombinant Human Erythropoietin Drugs Consumption Forecast by Region (2024-2029) & (K Units)
Table 16. World Short-acting Recombinant Human Erythropoietin Drugs Production Value by Manufacturer (2018-2023) & (USD Million)
Table 17. Production Value Market Share of Key Short-acting Recombinant Human Erythropoietin Drugs Producers in 2022
Table 18. World Short-acting Recombinant Human Erythropoietin Drugs Production by Manufacturer (2018-2023) & (K Units)
Table 19. Production Market Share of Key Short-acting Recombinant Human Erythropoietin Drugs Producers in 2022
Table 20. World Short-acting Recombinant Human Erythropoietin Drugs Average Price by Manufacturer (2018-2023) & (US$/Unit)
Table 21. Global Short-acting Recombinant Human Erythropoietin Drugs Company Evaluation Quadrant
Table 22. World Short-acting Recombinant Human Erythropoietin Drugs Industry Rank of Major Manufacturers, Based on Production Value in 2022
Table 23. Head Office and Short-acting Recombinant Human Erythropoietin Drugs Production Site of Key Manufacturer
Table 24. Short-acting Recombinant Human Erythropoietin Drugs Market: Company Product Type Footprint
Table 25. Short-acting Recombinant Human Erythropoietin Drugs Market: Company Product Application Footprint
Table 26. Short-acting Recombinant Human Erythropoietin Drugs Competitive Factors
Table 27. Short-acting Recombinant Human Erythropoietin Drugs New Entrant and Capacity Expansion Plans
Table 28. Short-acting Recombinant Human Erythropoietin Drugs Mergers & Acquisitions Activity
Table 29. United States VS China Short-acting Recombinant Human Erythropoietin Drugs Production Value Comparison, (2018 & 2022 & 2029) & (USD Million)
Table 30. United States VS China Short-acting Recombinant Human Erythropoietin Drugs Production Comparison, (2018 & 2022 & 2029) & (K Units)
Table 31. United States VS China Short-acting Recombinant Human Erythropoietin Drugs Consumption Comparison, (2018 & 2022 & 2029) & (K Units)
Table 32. United States Based Short-acting Recombinant Human Erythropoietin Drugs Manufacturers, Headquarters and Production Site (States, Country)
Table 33. United States Based Manufacturers Short-acting Recombinant Human Erythropoietin Drugs Production Value, (2018-2023) & (USD Million)
Table 34. United States Based Manufacturers Short-acting Recombinant Human Erythropoietin Drugs Production Value Market Share (2018-2023)
Table 35. United States Based Manufacturers Short-acting Recombinant Human Erythropoietin Drugs Production (2018-2023) & (K Units)
Table 36. United States Based Manufacturers Short-acting Recombinant Human Erythropoietin Drugs Production Market Share (2018-2023)
Table 37. China Based Short-acting Recombinant Human Erythropoietin Drugs Manufacturers, Headquarters and Production Site (Province, Country)
Table 38. China Based Manufacturers Short-acting Recombinant Human Erythropoietin Drugs Production Value, (2018-2023) & (USD Million)
Table 39. China Based Manufacturers Short-acting Recombinant Human Erythropoietin Drugs Production Value Market Share (2018-2023)
Table 40. China Based Manufacturers Short-acting Recombinant Human Erythropoietin Drugs Production (2018-2023) & (K Units)
Table 41. China Based Manufacturers Short-acting Recombinant Human Erythropoietin Drugs Production Market Share (2018-2023)
Table 42. Rest of World Based Short-acting Recombinant Human Erythropoietin Drugs Manufacturers, Headquarters and Production Site (States, Country)
Table 43. Rest of World Based Manufacturers Short-acting Recombinant Human Erythropoietin Drugs Production Value, (2018-2023) & (USD Million)
Table 44. Rest of World Based Manufacturers Short-acting Recombinant Human Erythropoietin Drugs Production Value Market Share (2018-2023)
Table 45. Rest of World Based Manufacturers Short-acting Recombinant Human Erythropoietin Drugs Production (2018-2023) & (K Units)
Table 46. Rest of World Based Manufacturers Short-acting Recombinant Human Erythropoietin Drugs Production Market Share (2018-2023)
Table 47. World Short-acting Recombinant Human Erythropoietin Drugs Production Value by Type, (USD Million), 2018 & 2022 & 2029
Table 48. World Short-acting Recombinant Human Erythropoietin Drugs Production by Type (2018-2023) & (K Units)
Table 49. World Short-acting Recombinant Human Erythropoietin Drugs Production by Type (2024-2029) & (K Units)
Table 50. World Short-acting Recombinant Human Erythropoietin Drugs Production Value by Type (2018-2023) & (USD Million)
Table 51. World Short-acting Recombinant Human Erythropoietin Drugs Production Value by Type (2024-2029) & (USD Million)
Table 52. World Short-acting Recombinant Human Erythropoietin Drugs Average Price by Type (2018-2023) & (US$/Unit)
Table 53. World Short-acting Recombinant Human Erythropoietin Drugs Average Price by Type (2024-2029) & (US$/Unit)
Table 54. World Short-acting Recombinant Human Erythropoietin Drugs Production Value by Application, (USD Million), 2018 & 2022 & 2029
Table 55. World Short-acting Recombinant Human Erythropoietin Drugs Production by Application (2018-2023) & (K Units)
Table 56. World Short-acting Recombinant Human Erythropoietin Drugs Production by Application (2024-2029) & (K Units)
Table 57. World Short-acting Recombinant Human Erythropoietin Drugs Production Value by Application (2018-2023) & (USD Million)
Table 58. World Short-acting Recombinant Human Erythropoietin Drugs Production Value by Application (2024-2029) & (USD Million)
Table 59. World Short-acting Recombinant Human Erythropoietin Drugs Average Price by Application (2018-2023) & (US$/Unit)
Table 60. World Short-acting Recombinant Human Erythropoietin Drugs Average Price by Application (2024-2029) & (US$/Unit)
Table 61. Amgen Basic Information, Manufacturing Base and Competitors
Table 62. Amgen Major Business
Table 63. Amgen Short-acting Recombinant Human Erythropoietin Drugs Product and Services
Table 64. Amgen Short-acting Recombinant Human Erythropoietin Drugs Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 65. Amgen Recent Developments/Updates
Table 66. Amgen Competitive Strengths & Weaknesses
Table 67. Johnson & Johnson Basic Information, Manufacturing Base and Competitors
Table 68. Johnson & Johnson Major Business
Table 69. Johnson & Johnson Short-acting Recombinant Human Erythropoietin Drugs Product and Services
Table 70. Johnson & Johnson Short-acting Recombinant Human Erythropoietin Drugs Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 71. Johnson & Johnson Recent Developments/Updates
Table 72. Johnson & Johnson Competitive Strengths & Weaknesses
Table 73. Roche Basic Information, Manufacturing Base and Competitors
Table 74. Roche Major Business
Table 75. Roche Short-acting Recombinant Human Erythropoietin Drugs Product and Services
Table 76. Roche Short-acting Recombinant Human Erythropoietin Drugs Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 77. Roche Recent Developments/Updates
Table 78. Roche Competitive Strengths & Weaknesses
Table 79. Kyowa Kirin Basic Information, Manufacturing Base and Competitors
Table 80. Kyowa Kirin Major Business
Table 81. Kyowa Kirin Short-acting Recombinant Human Erythropoietin Drugs Product and Services
Table 82. Kyowa Kirin Short-acting Recombinant Human Erythropoietin Drugs Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 83. Kyowa Kirin Recent Developments/Updates
Table 84. Kyowa Kirin Competitive Strengths & Weaknesses
Table 85. LG Chem Basic Information, Manufacturing Base and Competitors
Table 86. LG Chem Major Business
Table 87. LG Chem Short-acting Recombinant Human Erythropoietin Drugs Product and Services
Table 88. LG Chem Short-acting Recombinant Human Erythropoietin Drugs Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 89. LG Chem Recent Developments/Updates
Table 90. LG Chem Competitive Strengths & Weaknesses
Table 91. Daewoong Pharmaceutical Basic Information, Manufacturing Base and Competitors
Table 92. Daewoong Pharmaceutical Major Business
Table 93. Daewoong Pharmaceutical Short-acting Recombinant Human Erythropoietin Drugs Product and Services
Table 94. Daewoong Pharmaceutical Short-acting Recombinant Human Erythropoietin Drugs Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 95. Daewoong Pharmaceutical Recent Developments/Updates
Table 96. Daewoong Pharmaceutical Competitive Strengths & Weaknesses
Table 97. Wockhardt Basic Information, Manufacturing Base and Competitors
Table 98. Wockhardt Major Business
Table 99. Wockhardt Short-acting Recombinant Human Erythropoietin Drugs Product and Services
Table 100. Wockhardt Short-acting Recombinant Human Erythropoietin Drugs Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 101. Wockhardt Recent Developments/Updates
Table 102. Wockhardt Competitive Strengths & Weaknesses
Table 103. CJ Healthcare Basic Information, Manufacturing Base and Competitors
Table 104. CJ Healthcare Major Business
Table 105. CJ Healthcare Short-acting Recombinant Human Erythropoietin Drugs Product and Services
Table 106. CJ Healthcare Short-acting Recombinant Human Erythropoietin Drugs Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 107. CJ Healthcare Recent Developments/Updates
Table 108. CJ Healthcare Competitive Strengths & Weaknesses
Table 109. 3SBio Basic Information, Manufacturing Base and Competitors
Table 110. 3SBio Major Business
Table 111. 3SBio Short-acting Recombinant Human Erythropoietin Drugs Product and Services
Table 112. 3SBio Short-acting Recombinant Human Erythropoietin Drugs Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 113. 3SBio Recent Developments/Updates
Table 114. 3SBio Competitive Strengths & Weaknesses
Table 115. Kexing Biopharm Basic Information, Manufacturing Base and Competitors
Table 116. Kexing Biopharm Major Business
Table 117. Kexing Biopharm Short-acting Recombinant Human Erythropoietin Drugs Product and Services
Table 118. Kexing Biopharm Short-acting Recombinant Human Erythropoietin Drugs Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 119. Kexing Biopharm Recent Developments/Updates
Table 120. Kexing Biopharm Competitive Strengths & Weaknesses
Table 121. Harbin Pharmaceutical Group Basic Information, Manufacturing Base and Competitors
Table 122. Harbin Pharmaceutical Group Major Business
Table 123. Harbin Pharmaceutical Group Short-acting Recombinant Human Erythropoietin Drugs Product and Services
Table 124. Harbin Pharmaceutical Group Short-acting Recombinant Human Erythropoietin Drugs Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 125. Harbin Pharmaceutical Group Recent Developments/Updates
Table 126. Beijing Four Rings Bio-Pharmaceutical Basic Information, Manufacturing Base and Competitors
Table 127. Beijing Four Rings Bio-Pharmaceutical Major Business
Table 128. Beijing Four Rings Bio-Pharmaceutical Short-acting Recombinant Human Erythropoietin Drugs Product and Services
Table 129. Beijing Four Rings Bio-Pharmaceutical Short-acting Recombinant Human Erythropoietin Drugs Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 130. Global Key Players of Short-acting Recombinant Human Erythropoietin Drugs Upstream (Raw Materials)
Table 131. Short-acting Recombinant Human Erythropoietin Drugs Typical Customers
Table 132. Short-acting Recombinant Human Erythropoietin Drugs Typical Distributors
LIST OF FIGURE
Figure 1. Short-acting Recombinant Human Erythropoietin Drugs Picture
Figure 2. World Short-acting Recombinant Human Erythropoietin Drugs Production Value: 2018 & 2022 & 2029, (USD Million)
Figure 3. World Short-acting Recombinant Human Erythropoietin Drugs Production Value and Forecast (2018-2029) & (USD Million)
Figure 4. World Short-acting Recombinant Human Erythropoietin Drugs Production (2018-2029) & (K Units)
Figure 5. World Short-acting Recombinant Human Erythropoietin Drugs Average Price (2018-2029) & (US$/Unit)
Figure 6. World Short-acting Recombinant Human Erythropoietin Drugs Production Value Market Share by Region (2018-2029)
Figure 7. World Short-acting Recombinant Human Erythropoietin Drugs Production Market Share by Region (2018-2029)
Figure 8. North America Short-acting Recombinant Human Erythropoietin Drugs Production (2018-2029) & (K Units)
Figure 9. Europe Short-acting Recombinant Human Erythropoietin Drugs Production (2018-2029) & (K Units)
Figure 10. China Short-acting Recombinant Human Erythropoietin Drugs Production (2018-2029) & (K Units)
Figure 11. Japan Short-acting Recombinant Human Erythropoietin Drugs Production (2018-2029) & (K Units)
Figure 12. Short-acting Recombinant Human Erythropoietin Drugs Market Drivers
Figure 13. Factors Affecting Demand
Figure 14. World Short-acting Recombinant Human Erythropoietin Drugs Consumption (2018-2029) & (K Units)
Figure 15. World Short-acting Recombinant Human Erythropoietin Drugs Consumption Market Share by Region (2018-2029)
Figure 16. United States Short-acting Recombinant Human Erythropoietin Drugs Consumption (2018-2029) & (K Units)
Figure 17. China Short-acting Recombinant Human Erythropoietin Drugs Consumption (2018-2029) & (K Units)
Figure 18. Europe Short-acting Recombinant Human Erythropoietin Drugs Consumption (2018-2029) & (K Units)
Figure 19. Japan Short-acting Recombinant Human Erythropoietin Drugs Consumption (2018-2029) & (K Units)
Figure 20. South Korea Short-acting Recombinant Human Erythropoietin Drugs Consumption (2018-2029) & (K Units)
Figure 21. ASEAN Short-acting Recombinant Human Erythropoietin Drugs Consumption (2018-2029) & (K Units)
Figure 22. India Short-acting Recombinant Human Erythropoietin Drugs Consumption (2018-2029) & (K Units)
Figure 23. Producer Shipments of Short-acting Recombinant Human Erythropoietin Drugs by Manufacturer Revenue ($MM) and Market Share (%): 2022
Figure 24. Global Four-firm Concentration Ratios (CR4) for Short-acting Recombinant Human Erythropoietin Drugs Markets in 2022
Figure 25. Global Four-firm Concentration Ratios (CR8) for Short-acting Recombinant Human Erythropoietin Drugs Markets in 2022
Figure 26. United States VS China: Short-acting Recombinant Human Erythropoietin Drugs Production Value Market Share Comparison (2018 & 2022 & 2029)
Figure 27. United States VS China: Short-acting Recombinant Human Erythropoietin Drugs Production Market Share Comparison (2018 & 2022 & 2029)
Figure 28. United States VS China: Short-acting Recombinant Human Erythropoietin Drugs Consumption Market Share Comparison (2018 & 2022 & 2029)
Figure 29. United States Based Manufacturers Short-acting Recombinant Human Erythropoietin Drugs Production Market Share 2022
Figure 30. China Based Manufacturers Short-acting Recombinant Human Erythropoietin Drugs Production Market Share 2022
Figure 31. Rest of World Based Manufacturers Short-acting Recombinant Human Erythropoietin Drugs Production Market Share 2022
Figure 32. World Short-acting Recombinant Human Erythropoietin Drugs Production Value by Type, (USD Million), 2018 & 2022 & 2029
Figure 33. World Short-acting Recombinant Human Erythropoietin Drugs Production Value Market Share by Type in 2022
Figure 34. Epoetin-alfa
Figure 35. Epoetin-beta
Figure 36. Darbepoetin-alfa
Figure 37. Others
Figure 38. World Short-acting Recombinant Human Erythropoietin Drugs Production Market Share by Type (2018-2029)
Figure 39. World Short-acting Recombinant Human Erythropoietin Drugs Production Value Market Share by Type (2018-2029)
Figure 40. World Short-acting Recombinant Human Erythropoietin Drugs Average Price by Type (2018-2029) & (US$/Unit)
Figure 41. World Short-acting Recombinant Human Erythropoietin Drugs Production Value by Application, (USD Million), 2018 & 2022 & 2029
Figure 42. World Short-acting Recombinant Human Erythropoietin Drugs Production Value Market Share by Application in 2022
Figure 43. Anemia
Figure 44. Kidney Disorders
Figure 45. Others
Figure 46. World Short-acting Recombinant Human Erythropoietin Drugs Production Market Share by Application (2018-2029)
Figure 47. World Short-acting Recombinant Human Erythropoietin Drugs Production Value Market Share by Application (2018-2029)
Figure 48. World Short-acting Recombinant Human Erythropoietin Drugs Average Price by Application (2018-2029) & (US$/Unit)
Figure 49. Short-acting Recombinant Human Erythropoietin Drugs Industry Chain
Figure 50. Short-acting Recombinant Human Erythropoietin Drugs Procurement Model
Figure 51. Short-acting Recombinant Human Erythropoietin Drugs Sales Model
Figure 52. Short-acting Recombinant Human Erythropoietin Drugs Sales Channels, Direct Sales, and Distribution
Figure 53. Methodology
Figure 54. Research Process and Data Source
